MaxCyte Raises 2026 Revenue Outlook to $34 Million
Key Facts
MaxCyte raised its total revenue outlook for 2026 to about $34 million in an announcement on October 14, following its core business performance in the third quarter. The new forecast compares with a previous range of $30 million to $32 million, according to an Investing report published on the day of the announcement. It also exceeds analysts' annual revenue estimate of $31.45 million cited in the same report. According to the company's disclosure on its investor relations website, it now expects core business revenue of about $28 million for the year. Its previous forecast for that business ranged from $25 million to $27 million, according to the Investing report.
Preliminary core business revenue totaled about $8.1 million in the third quarter of 2026, according to the company's official disclosure. MaxCyte said this represented 26% year-on-year revenue growth for that business. Core business revenue in the third quarter of 2025 was $6.4 million, according to the preliminary announcement for the comparable period. Preliminary revenue from the Strategic Platform License program exceeded $1.0 million in the third quarter of the current year. That compares with program revenue of $0.4 million in the corresponding quarter of the previous year, according to the company's disclosure published at the time.
The company attributed the quarter's outperformance to "a large customer bringing forward instrument purchases," according to the Investing report's account of the announcement. These purchases were originally expected in the fourth quarter, meaning their timing contributed to third-quarter performance. Chief Executive Maher Masoud said the revised outlook reflected about 15% year-on-year growth in core business revenue in the second half of 2026. The company said the reported third-quarter revenue was preliminary and unaudited, according to the report published on the day of the announcement. These results remain subject to change following completion of closing and review procedures, ahead of the release of full financial results.
MaxCyte raised its annual revenue outlook for the Strategic Platform License program to about $6 million, according to its official disclosure. The previous revenue forecast for the program was about $5 million, according to Investing's report on the outlook update. The new annual estimate includes about $4 million in milestone payments under the program. It also includes about $2 million in commercial royalties, alongside the milestone payments cited by the company. MaxCyte's platform uses flow electroporation technology for cell engineering, according to its filing with the U.S. Securities and Exchange Commission.
The update follows core business revenue of $6.5 million in the second quarter of 2026, according to the company's filing with the U.S. regulator. Revenue from that business in the second quarter was down 21% from the same period a year earlier. The company's net loss for that quarter was $8.9 million, according to the same financial filing. Cash, cash equivalents and investments totaled $141.9 million as of June 30, 2026. In response to the latest announcement, Investing's October 14 report said MXCT shares jumped 25% during trading.
Regarding Strategic Platform License program partnerships, management said they include two pivotal trials, according to the official disclosure. It added that these two trials could lead to approvals in the year following the announcement. Securing those approvals remains a possibility raised by management, with no guarantee it will materialize. MaxCyte will announce its full third-quarter financial results on November 10, 2026, according to the Investing report. The earnings release will include royalty revenue among the financial details the company will publish for the period.